Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04986241
Other study ID # CardioRehab Bank Study
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 20, 2019
Est. completion date June 20, 2023

Study information

Verified date October 2022
Source University of Sao Paulo General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Statins are part of one of the largest groups of drugs prescribed worldwide used in the treatment of dyslipidemia. Despite the good therapeutic results of statins and their good tolerance on the part of patients, some adverse effects may occur during treatment. In skeletal muscle, statins can lead to mitochondrial dysfunction characterized by decreased adenosine triphosphate production, decreased oxidative phosphorylation capacity, increased concentration of reactive oxygen species, and decreased mitochondrial biogenesis. Cardiorespiratory fitness is a physiological indicator that corresponds to the integration of the cardiovascular, pulmonary, muscular, and cellular (mitochondria) systems in capturing, transporting and using oxygen, commonly expressed as the maximum oxygen consumption. Several studies show a strong association of lower cardiorespiratory capacity with an increased risk of mortality from cardiovascular disease and mortality from all causes. Combining the use of statins with lifestyle changes has been suggested in many medical guidelines. Physical exercise plays a fundamental role in improving cardiorespiratory fitness and controlling dyslipidemia. However, some studies suggest that the association of statin with physical training can negatively influence the adaptation and improvement of cardiorespiratory capacity. On the other hand, some studies show that the combination of statin and physical exercise does not negatively interfere with the maximum oxygen consumption. To determine the impact of statins on cardiorespiratory fitness and adaptation to physical exercise, the investigators will use the database of the Cardiovascular Rehabilitation and Exercise Physiology Department at Heart Institute (Sao Paulo, Brazil), which currently has 33,804 maximal cardiopulmonary exercise tests. This large database, which is the gold standard of cardiorespiratory capacity (maximum oxygen consumption), will be used retrospectively with relevant information and a huge number of participants. Therefore, the aim of this study will be to explore a large database to assess the effect of the use of statins and their relationship with cardiorespiratory capacity in physically active and sedentary individuals (with and without heart failure).


Description:

The investigators will use the database of the Cardiovascular Rehabilitation and Exercise Physiology Department at Heart Institute (Sao Paulo, Brazil) in an exploratory manner. The investigators will use filters to perform different analyzes and sub-analyses with different groups of patients. The investigators aimed to compare patients using statins and healthy controls (not using medications). The analysis strategy will be as following: 1) physically active and sedentary patients with normal cardiac function using statins and peak oxygen consumption (peak VO2); 2) physically active and sedentary patients with cardiac dysfunction (heart failure) using statins and peak VO2; 3) comparison between the hydrophilic and lipophilic classes of statins; 4) comparison between men and women; 5) retrospective information on clinical and laboratory variables and 6) test information on cardiorespiratory capacity and several variables associated with the mortality outcome. The participants underwent cardiopulmonary exercise testing on a treadmill or bike (SensorMedics - Vmax Analyzer Assembly, Encore 29S) following a ramp protocol with constant load increase until exhaustion. Cardiorespiratory capacity will be determined by peak VO2, assessed at maximum exercise intensity, with a respiratory exchange ratio >1.10.


Recruitment information / eligibility

Status Completed
Enrollment 18557
Est. completion date June 20, 2023
Est. primary completion date June 20, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Maximal Cardiopulmonary Test on treadmill or bike. - Test considered maximum from the metabolic point of view (Respiratory Quotient >1.10). Exclusion Criteria: - Incomplete patient data. - Incomplete exam data. - Chronic obstructive pulmonary disease - Diagnosis of cancer

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Statin
Chronic use of statin prescribed previously by the assistant physician.
Other:
Physical activity
Physically active participants
Sedentary
Physically inactive or sedentary participants.

Locations

Country Name City State
Brazil Marcelo Rodrigues dos Santos São Paulo Sao Paulo

Sponsors (1)

Lead Sponsor Collaborator
University of Sao Paulo General Hospital

Country where clinical trial is conducted

Brazil, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cardiorespiratory Fitness To determine whether the use of statins impairs the adaptation of the cardiorespiratory fitness in physically active individuals, with and without left ventricular dysfunction (heart failure), when compared with a matched sedentary control group. From 1998 to 2017
Secondary Types of statins in Cardiorespiratory Fitness To determine whether the type of statins (lipophilic or hydrophilic) has any adverse effect on the cardiorespiratory fitness in physically active individuals, with and without left ventricular dysfunction (heart failure), when compared with a matched sedentary control group. From 1998 to 2017
Secondary Sex differences To determine whether sex (men and women) is associated with statins and cardiorespiratory fitness impairment. From 1998 to 2017
Secondary Cardiovascular mortality To determine the association of functional capacity and cardiorespiratory fitness with cardiovascular mortality. From 1998 to 2017
Secondary All-cause mortality To determine the association of functional capacity and cardiorespiratory fitness with all-cause mortality. From 1998 to 2017
See also
  Status Clinical Trial Phase
Recruiting NCT04499859 - Low Dose Rosuvastatin Plus Ezetimibe Versus High-dose Rosuvastatin in AMI Phase 4
Completed NCT03001076 - Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility) Phase 3
Completed NCT02988115 - Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant Phase 3
Recruiting NCT05332158 - Medicines Gaps Study N/A
Not yet recruiting NCT06381947 - Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients Phase 4
Completed NCT03874156 - MUscle Side-Effects of Atorvastatin in Coronary Patients Phase 4
Not yet recruiting NCT06262685 - Efficacy, Safety and Cost-efficacy of a Pre-emptive Genotyping Strategy in Patients Receiving Statins Phase 4
Completed NCT05806723 - Effects of High Intensity Statin Therapy on Steroid Hormones and Vitamin D in Type 2 Diabetic Men Phase 4
Active, not recruiting NCT03653663 - NIRS to Diagnose SAMS Phase 4
Completed NCT02993406 - Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo Phase 3
Recruiting NCT04069598 - Statin Intolerance in Patients With Myocardial Infarction
Completed NCT04453735 - MUscle Side-Effects of Atorvastatin in Coronary Patients (MUSE) -Follow-up Study Phase 4
Terminated NCT04507373 - 7T Magnetic Resonance Spectroscopy and Skeletal Muscle Biopsy Findings in Statin Associated Adverse Muscle Events Phase 4